Episode
Episode 50. Quadruplets in Newly Diagnosed Transplant-Ineligible Myeloma with Dr. Timothy Schmidt
- Podcast
- Blood Cancer Talks
- Published
- Aug 29, 2024
- Duration seconds
- 2499
- Processing state
not_requested- Canonical source
- https://share.transistor.fm/s/6e20d230
Actions
POST https://stenobird.com/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-50-quadruplets-in-newly-diagnosed-transplant-ineligible-myeloma-with-dr-timothy-schmidt/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-50-quadruplets-in-newly-diagnosed-transplant-ineligible-myeloma-with-dr-timothy-schmidt.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode, we discuss the management of newly diagnosed transplant in-eligible multiple myeloma with Dr. Timothy Schmidt, with a special focus on IMROZ and BENEFIT RCTs testing quadruplets in this space. Here are the key papers we discussed: 1. MAIA trial (Daratumumab-Lenalidomide-Dexamethasone [DRd] vs Rd in newly diagnosed transplant ineligible myeloma): https://pubmed.ncbi.nlm.nih.gov/34655533/ 2. S0777 trial (VRd vs Rd in newly diagnosed myeloma [transplant-ineligible or transplant-deferred]): https://pubmed.ncbi.nlm.nih.gov/32393732/ 3. IMROZ trial (Isatuximab-VRd vs VRd in newly diagnosed transplant-ineligible myeloma): https://pubmed.ncbi.nlm.nih.gov/38832972/ 4. IFM-2020/BENEFIT trial (Isatuximab-VRd vs Isatuximab-Rd in newly diagnosed transplant-ineligible myeloma): https://pubmed.ncbi.nlm.nih.gov/38830994/ 5. GEM2017FIT trial (VMP-Rd vs KRd vs Dara-KRd in newly diagnosed transplant-ineligible myeloma): https://ashpublications.org/blood/article/142/Supplement%201/209/500199